Literature DB >> 19920055

The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.

Robert B Parker1, S Casey Laizure.   

Abstract

Ethanol decreases the clearance of cocaine by inhibiting the hydrolysis of cocaine to benzoylecgonine and ecgonine methyl ester by carboxylesterases, and there is a large body of literature describing this interaction as it relates to the abuse of cocaine. In this study, we describe the effect of intravenous ethanol on the pharmacokinetics of cocaine after intravenous and oral administration in the dog. The intent is to determine the effect ethanol has on metabolic hydrolysis using cocaine metabolism as a surrogate marker of carboxylesterase activity. Five dogs were administered intravenous cocaine alone, intravenous cocaine after ethanol, oral cocaine alone, and oral cocaine after ethanol on separate study days. Cocaine, benzoylecgonine, and cocaethylene concentrations were determined by high-performance liquid chromatography. Cocaine had poor systemic bioavailability with an area under the plasma concentration-time curve that was approximately 4-fold higher after intravenous than after oral administration. The coadministration of ethanol and cocaine resulted in a 23% decrease in the clearance of intravenous cocaine and a 300% increase in the bioavailability of oral cocaine. Cocaine behaves as a high extraction drug, which undergoes first-pass metabolism in the intestines and liver that is profoundly inhibited by ethanol. We infer from these results that ethanol could inhibit the hydrolysis of other drug compounds subject to hydrolysis by carboxylesterases. Indeed, there are numerous commonly prescribed drugs with significant carboxylesterase-mediated metabolism such as enalapril, lovastatin, irinotecan, clopidogrel, prasugrel, methylphenidate, meperidine, and oseltamivir that may interact with ethanol. The clinical significance of the interaction of ethanol with specific drugs subject to carboxylesterase hydrolysis is not well recognized and has not been adequately studied.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920055      PMCID: PMC2812060          DOI: 10.1124/dmd.109.030056

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  48 in total

1.  Current progress on esterases: from molecular structure to function.

Authors:  Tetsuo Satoh; Palmer Taylor; William F Bosron; Sonal P Sanghani; Masakiyo Hosokawa; Bert N La Du
Journal:  Drug Metab Dispos       Date:  2002-05       Impact factor: 3.922

2.  Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases.

Authors:  S Casey Laizure; Timothy Mandrell; Naomi M Gades; Robert B Parker
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

3.  Cocaine and alcohol interactions in the rat: effect of cocaine and alcohol pretreatments on cocaine pharmacokinetics and pharmacodynamics.

Authors:  W J Pan; M A Hedaya
Journal:  J Pharm Sci       Date:  1999-12       Impact factor: 3.534

4.  Naphthoxylactic acid after single and long-term doses of propranolol.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

5.  Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats.

Authors:  L Sun; C E Lau
Journal:  Drug Metab Dispos       Date:  2001-09       Impact factor: 3.922

6.  Human carboxylesterase 1: from drug metabolism to drug discovery.

Authors:  M R Redinbo; S Bencharit; P M Potter
Journal:  Biochem Soc Trans       Date:  2003-06       Impact factor: 5.407

7.  Pharmacokinetics of intravenous cocaine across the menstrual cycle in rhesus monkeys.

Authors:  Suzette M Evans; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

8.  Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide.

Authors:  R Osborne; S Joel; D Trew; M Slevin
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

9.  The pharmacology of cocaethylene in humans following cocaine and ethanol administration.

Authors:  Debra S Harris; E Thomas Everhart; John Mendelson; Reese T Jones
Journal:  Drug Alcohol Depend       Date:  2003-11-24       Impact factor: 4.492

10.  The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

Authors:  Eric T Williams; Karen O Jones; G Douglas Ponsler; Shane M Lowery; Everett J Perkins; Steven A Wrighton; Kenneth J Ruterbories; Miho Kazui; Nagy A Farid
Journal:  Drug Metab Dispos       Date:  2008-03-27       Impact factor: 3.922

View more
  11 in total

1.  Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry.

Authors:  Zhe-Yi Hu; S Casey Laizure; Vanessa L Herring; Robert B Parker
Journal:  Rapid Commun Mass Spectrom       Date:  2014-06-15       Impact factor: 2.419

2.  Intravenous lipid emulsion to treat suspected cocaine toxicosis in a dog.

Authors:  Kirsty Royle; Carsten Bandt
Journal:  Can Vet J       Date:  2020-01       Impact factor: 1.008

3.  Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.

Authors:  Marion A Coe; Rebecca A Jufer Phipps; Edward J Cone; Sharon L Walsh
Journal:  J Anal Toxicol       Date:  2018-06-01       Impact factor: 3.367

4.  Effects of alcohol on human carboxylesterase drug metabolism.

Authors:  Robert B Parker; Zhe-Yi Hu; Bernd Meibohm; S Casey Laizure
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

Review 5.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

6.  Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.

Authors:  S Casey Laizure; Robert B Parker; Vanessa L Herring; Zhe-Yi Hu
Journal:  Drug Metab Dispos       Date:  2013-11-08       Impact factor: 3.922

7.  Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans.

Authors:  Kennerly S Patrick; Arthur B Straughn; Owen T Reeves; Hilary Bernstein; Guinevere H Bell; Erica R Anderson; Robert J Malcolm
Journal:  Drug Metab Dispos       Date:  2012-10-25       Impact factor: 3.922

8.  Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.

Authors:  Zhe-Yi Hu; Andrea N Edginton; S Casey Laizure; Robert B Parker
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

9.  In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent.

Authors:  Jianmei Wu; Jiajiu Shaw; Sarah Dubaisi; Frederick Valeriote; Jing Li
Journal:  Drug Metab Dispos       Date:  2014-09-23       Impact factor: 3.922

10.  Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; Arthur B Straughn; Owen T Reeves; Hilary Bernstein; Jian Shi; Heather J Johnson; Joshua M Knight; Aaron T Smith; Robert J Malcolm; John S Markowitz
Journal:  J Clin Psychopharmacol       Date:  2017-08       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.